NCT04260373 is a Phase 1 clinical trial of [14C]SHR4640 in Healthy Adult Male Volunteers, sponsored by Jiangsu HengRui Medicine Co., Ltd..

Who is sponsoring NCT04260373?

NCT04260373 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT04260373?

Interventions in NCT04260373: [14C]SHR4640.

What condition does NCT04260373 study?

NCT04260373 studies Healthy Adult Male Volunteers.

Is NCT04260373 still recruiting?

NCT04260373 is currently completed. Last updated 14 April 2020.

Last reviewed 2020-04-14 · How we verify

NCT04260373

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.

Completed Phase 1 Last updated 14 April 2020

What this trial tests

Phase 1 trial testing [14C]SHR4640 in Healthy Adult Male Volunteers in 6 participants. Completed in 3 April 2020.

Timeline

19 March 2020

Primary endpoint
3 April 2020

3 April 2020

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	6
Start date	19 March 2020
Primary completion	3 April 2020
Estimated completion	3 April 2020
Sites	1 location across China

Drugs / interventions tested

[14C]SHR4640 — full drug profile →

Conditions studied

Healthy Adult Male Volunteers — all drugs for Healthy Adult Male Volunteers →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, male only, with Healthy Adult Male Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]SHR4640 in Chinese healthy adult male volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Review of Urate-Lowering Therapeutics: From the Past to the Future.
Jenkins C, Hwang JH, Kopp JB, Winkler CA, et al · · 2022 · cited 38× · PMID 36081938 · DOI 10.3389/fphar.2022.925219

Verify or expand the search:

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04260373 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 14 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04260373.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing